According to a new report from Intel Market Research, the global Pembrolizumab market was valued at USD 21.8 billion in 2025 and is projected to grow from USD 24.3 billion in 2026 to USD 42.7 billion by 2034, exhibiting a robust CAGR of 7.3% during the forecast period. This growth is driven by increasing cancer prevalence, rising immunotherapy adoption, expanding regulatory approvals for new...

According to a newly published market research report by 24LifeSciences, global TIL cell therapy market was valued at USD 100 million in 2025 and is projected to reach USD 1,116 million by 2034, growing at a compound annual growth rate (CAGR) of 43.3% during the forecast period 2026-2034. Tumor-Infiltrating Lymphocyte (TIL) therapy represents a breakthrough in adoptive cell therapy for advanced...